Calidi Biotherapeutics, Inc. Research and Development Expense
Calidi Biotherapeutics, Inc. (CLDI) reported Research and Development Expense of $2.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $2.56M, a 1.35% decline year-over-year.
- Calidi Biotherapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $2.59M, a 6.68% increase year-over-year.
- Calidi Biotherapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $2.36M, a 29.92% increase year-over-year.
- Calidi Biotherapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $2.36M, a 9.66% increase year-over-year.
- Calidi Biotherapeutics, Inc. research and development expense for fiscal 2025 was $9.74M, a 9.68% increase from fiscal 2024.
- Calidi Biotherapeutics, Inc. research and development expense for fiscal 2024 was $8.88M, a 31.75% decline from fiscal 2023.
- Calidi Biotherapeutics, Inc. research and development expense for fiscal 2023 was $13.01M, a 79.25% increase from fiscal 2022.
- Calidi Biotherapeutics, Inc. research and development expense for fiscal 2022 was $7.26M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.56M 10-Q · filed 2026-08-13 | $5.14M 10-Q · filed 2026-08-13 | $7.50M derived: sum of 3 quarters · filed 2026-08-13 | $9.86M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.59M 10-Q · filed 2026-05-14 | $4.95M derived: sum of 2 quarters · filed 2026-05-14 | $7.31M derived: sum of 3 quarters · filed 2026-05-14 | $9.90M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $4.72M derived: sum of 2 quarters · filed 2026-03-27 | $7.31M derived: sum of 3 quarters · filed 2026-08-13 | $9.74M 10-K · filed 2026-03-27 |
| 2025-09-30 | $2.36M 10-Q · filed 2025-11-13 | $4.95M derived: sum of 2 quarters · filed 2026-08-13 | $7.38M 10-Q · filed 2025-11-13 | $9.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $2.59M 10-Q · filed 2026-08-13 | $5.02M 10-Q · filed 2026-08-13 | $6.83M derived: sum of 3 quarters · filed 2026-08-13 | $8.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.42M 10-Q · filed 2026-05-14 | $4.24M derived: sum of 2 quarters · filed 2026-05-14 | $6.39M derived: sum of 3 quarters · filed 2026-05-14 | $8.56M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $3.97M derived: sum of 2 quarters · filed 2026-03-27 | $6.13M derived: sum of 3 quarters · filed 2026-03-27 | $8.88M 10-K · filed 2026-03-27 |
| 2024-09-30 | $2.15M 10-Q · filed 2025-11-13 | $4.32M derived: sum of 2 quarters · filed 2025-11-13 | $7.06M 10-Q · filed 2025-11-13 | $11.02M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.17M 10-Q · filed 2025-08-08 | $4.91M 10-Q · filed 2025-08-08 | $8.87M derived: sum of 3 quarters · filed 2025-08-08 | $12.12M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $2.74M 10-Q · filed 2025-05-14 | $6.70M derived: sum of 2 quarters · filed 2025-05-14 | $9.95M derived: sum of 3 quarters · filed 2025-05-14 | $13.13M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $7.21M derived: sum of 2 quarters · filed 2025-03-31 | $10.39M derived: sum of 3 quarters · filed 2025-03-31 | $13.01M 10-K · filed 2025-03-31 |
| 2023-09-30 | $3.25M 10-Q · filed 2024-11-12 | $6.43M derived: sum of 2 quarters · filed 2024-11-12 | $9.05M 10-Q · filed 2024-11-12 | $11.31M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $3.18M 10-Q · filed 2024-08-13 | $5.80M 10-Q · filed 2024-08-13 | $8.06M derived: sum of 3 quarters · filed 2024-08-13 | $10.01M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $2.62M 10-Q · filed 2024-05-14 | $4.88M derived: sum of 2 quarters · filed 2024-05-14 | $6.83M derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $4.21M derived: sum of 2 quarters · filed 2024-03-15 | $7.26M 10-K · filed 2024-03-15 | |
| 2022-09-30 | $1.95M 10-Q · filed 2023-11-14 | $4.99M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |